The Online Investor
Biotechnology M&A image Biotechnology M&A » By The Online Investor Staff, updated Tue., Apr. 20, 3:29 AM Recent mergers and acquisitions in the Biotechnology M&A category.

Slide #38. Sorrento Therapeutics, Inc. Concortis Biosystems, Corp

Acquirer: Sorrento Therapeutics, Inc. (NASDAQ:SRNE)
Acquiree: Concortis Biosystems, Corp
Details: Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento) announced today the entry into a definitive agreement to acquire San Diego-based Concortis Biosystems, Corp. in a deal that provides Sorrento with a comprehensive technology platform for generation of antibody drug conjugates (ADC). Under the terms of the agreement dated November 11, 2013, subject to satisfaction of certain closing conditions, upon closing, Sorrento will issue an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders.

Sorrento Therapeutics is a clinical stage and commercial biopharma company focused on delivering therapies to patients and their families. Co. has two segments: The Sorrento Therapeutics segment, which is organized around its Immune-Oncology therapeutic area, using its proprietary G-MAB™ antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include proprietary chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, antibody drug conjugates as well as bispecific antibody approaches. The Scilex segment is mainly organized around Co.'s non-opioid pain management operations.

SRNE SEC Filing Email Alerts Service


Open the SRNE Page at The Online Investor »

Company Name: 
Sorrento Therapeutics Inc
Website: 
www.sorrentotherapeutics.com
Sector: 
Biotechnology
Number of ETFs Holding SRNE: 
24
Total Market Value Held by ETFs: 
$194.76M
Total Market Capitalization: 
$2.09B
% of Market Cap. Held by ETFs: 
9.34%
 

Open the SRNE Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes



Strong Buy (4.00 out of 4)
79th percentile
(ranked higher than approx. 79% of all stocks covered)

Analysts' Target Price:
SRNE Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Biotechnology M&A - Slide 38 of 83 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.